| Today’s Big NewsNov 25, 2024 |
|
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
| By Nick Paul Taylor Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing secondary and exploratory biomarker endpoints, the biotech has pulled the plug on another phase 3 trial and an open-label extension. |
|
|
|
By Nick Paul Taylor A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy has missed its primary endpoint. The biotech plans to talk to the FDA about the next steps in SMA and is stepping up its interest in obesity on the strength of the data. |
By Gabrielle Masson Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate candidates into the clinic. |
Sponsored by Dell Technologies Head of Life Sciences Strategy Alex Long shares key insights and advice for IT professionals working to enable healthcare’s technology transformation. |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now.
|
|
By Fraiser Kansteiner President-elect Donald Trump has named Johns Hopkins surgeon and author Martin Makary, M.D., as his choice for FDA commissioner during his upcoming term. |
Sponsored by Questex Discover the trailblazers shaping the future of healthcare, biotech, and pharma at the Fierce 50 Awards Gala. |
By James Waldron HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. |
By James Waldron Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has decided to buy the vaccine program. |
By Kevin Dunleavy The FDA has signed off on BridgeBio's Attruby (acoramidis), a potential blockbuster to treat patients with the rare heart disease transthyretin amyloid cardiomyopathy. With the nod, BridgeBio will challenge Pfizer’s powerhouse Vyndaqel franchise, which dominates the indication. |
By Noah Tong The health equity index might get rolled back in the next administration and there may be a bipartisan consensus forming around Medicare Advantage and star ratings. |
By Darren Incorvaia Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release immune checkpoint inhibitors that shrank intestinal tumors in mice with colorectal cancer. |
By Kevin Dunleavy After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue increases among the top companies in the biopharma industry, there was a new growth champion in the third quarter. With a 32% revenue increase, Pfizer jumped into the top spot. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
